Stock Price Quote

UNICHEM LABORATORIES LTD.

NSE : UNICHEMLABBSE : 506690ISIN CODE : INE351A01035Industry : Pharmaceuticals & DrugsHouse : Private
BSE590.3012.85 (+2.23 %)
PREV CLOSE ( ) 577.45
OPEN PRICE ( ) 581.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 6087
TODAY'S LOW / HIGH ( )577.45 599.45
52 WK LOW / HIGH ( )365.35 606.85
NSE591.4015.4 (+2.67 %)
PREV CLOSE( ) 576.00
OPEN PRICE ( ) 579.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 591.40 (88)
VOLUME 50381
TODAY'S LOW / HIGH( ) 577.95 599.95
52 WK LOW / HIGH ( )366.4 607.4
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 22-08 1962
Management Info
Prakash A Mody - Chairman Pabitrakumar Kalipada Bhattacharyya - Managing Director
Registered Office

Address Unichem Bhavan,Prabhat Estate, Off S V Raod,Jogeshwari (West),
Mumbai,
Maharashtra-400102

Phone 022 - 66888333

Email shares@unichemlabs.com

Website www.unichemlabs.com

Registrars Details
Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX

NEWS

26Mar Unichem Laboratories informs about clo
Unichem Laboratories has informed that pursuant to the Company's code of..
23Mar Unichem Laboratories informs about res
Pursuant to Regulation 44(3) of SEBI (Listing Obligations and Disclosure..
22Feb Unichem Laboratories informs about pre
Unichem Laboratories has informed that it enclosed the publication dated..
21Feb Unichem Laboratories informs about pos
Unichem Laboratories has informed that it enclosed the Postal Ballot Not..
21Feb Appointment of Director
Inter alia, considered and approved:- Based on the recommendations of N..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit693.009999999999-2997
Gross Profit 693.009999999999 -2790.88
Operating Profit 292.649999999999-510.650000000001
Net Sales 3624.2710724.32

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2621.00 (5.75%)
M.Cap ( in Cr)1619.26
Glaxosmithkline Phar (BSE)
peergroup  2079.80 (7.06%)
M.Cap ( in Cr)35233.07
TTK Healthcare (BSE)
peergroup  1591.35 (5.77%)
M.Cap ( in Cr)2248.63
Cipla (BSE)
peergroup  1398.80 (3.79%)
M.Cap ( in Cr)112938.41
Torrent Pharma (BSE)
peergroup  2685.00 (1.85%)
M.Cap ( in Cr)90872.60

Shareholding Pattern

MUTUAL FUNDS/UTI 9.77%
PROMOTERS 70.22%
NON-INSTITUTION 17.61%
FI/BANKS/INSURANCE 0.26%
GOVERNMENT 0%
FII 0%

About Unichem Laboratories Ltd.

Unichem Laboratories Ltd. was incorporated in the year 1962. Its today's share price is 590.3. Its current market capitalisation stands at Rs 4156.05 Cr. In the latest quarter, company has reported Gross Sales of Rs. 10724.32 Cr and Total Income of Rs.11142.8 Cr. The company's management includes Pradeep Bhandari, Priti Puri, Pabitrakumar Kalipada Bhattacharyya, Pranay Premchand Godha, Prakash A Mody.

It is listed on the BSE with a BSE Code of 506690 , NSE with an NSE Symbol of UNICHEMLAB and ISIN of INE351A01035. It's Registered office is at Unichem Bhavan,Prabhat Estate, Off S V Raod,Jogeshwari (West)Mumbai-400102, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BD Jokhakar & Co, NA Shah Associates LLP

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.